Ontology highlight
ABSTRACT: Background
Chronic-active antibody mediated rejection (c-aABMR) is a major contributor to long-term kidney allograft loss. We conducted a retrospective analysis to establish the efficacy of treatment with intravenous immunoglobulins (IVIG) and pulse methylprednisolone (MP) of patients with c-aABMR.Methods
Sixty-nine patients, in the period 2005-2017, with the diagnosis (suspicious for) c-aABMR that were treated with IVIG and MP were included. Patients were administered three doses of 1?g intravenous MP combined with a single dose of IVIG (1?g/kg body weight). Primary outcome was the decline in allograft function one year post treatment. Responders to IVIG-MP therapy were defined by an eGFR one year after treatment which was at least 25% above the projected allograft function.Results
Patients showed an average decline in eGFR of 9.8?ml/min/1.73m2 the year prior to treatment. Following treatment, a significant reduction (p?2). Furthermore, a significant improvement in proteinuria was observed upon treatment (p?ConclusionsMore than 60% of patients with c-aABMR with a progressive decline in eGFR respond favorably to treatment with IVIG-MP resulting in a significant improvement of graft survival (Sablik, Am J Transplant 18, 2018).
SUBMITTER: Sablik KA
PROVIDER: S-EPMC6567552 | biostudies-literature | 2019 Jun
REPOSITORIES: biostudies-literature
Sablik Kasia A KA Clahsen-van Groningen Marian C MC Looman Caspar W N CWN Damman Jeffrey J van Agteren Madelon M Betjes Michiel G H MGH
BMC nephrology 20190614 1
<h4>Background</h4>Chronic-active antibody mediated rejection (c-aABMR) is a major contributor to long-term kidney allograft loss. We conducted a retrospective analysis to establish the efficacy of treatment with intravenous immunoglobulins (IVIG) and pulse methylprednisolone (MP) of patients with c-aABMR.<h4>Methods</h4>Sixty-nine patients, in the period 2005-2017, with the diagnosis (suspicious for) c-aABMR that were treated with IVIG and MP were included. Patients were administered three dose ...[more]